Levofloxacin-Proliposomes: Opportunities for Use in Lung Tuberculosis

Pharmaceutics

Volumn 4, Issue 3, 2012, Pages 385-412

  Rojanarat, Wipaporn ^a   Nakpheng, Titpawan ^a   Thawithong, Ekawat ^a   Yanyium, Niracha ^a   Srichana, Teerapol ^a  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

Author keywords

dry powder inhaler; immunological response; levofloxacin; proliposome; tuberculosis

Indexed keywords

EID: 85168354522     PISSN: None     EISSN: 19994923     Source Type: Journal    
DOI: 10.3390/pharmaceutics4030385     Document Type: Article

References (37)

1. World Health Organization Global tuberculosis control: WHO report 2010 (accessed on 23 April 2011) Available online:http://www.who.int/tb/publications/global_report/2010/en/index.html
2. Das P. Horton R. Tuberculosis-time to accelerate progress Lancet 2010 375 1755 1757
3. Ghebreyesus T.A. Kazatchkine M. Sidibe M. Nakatani H. Tuberculosis and HIV: Time for an intensified response Lancet 2010 375 1757 1758
4. Frieden T.R. Stering T.R. Munstiff S.S. Watt C.J. Dye C. Tuberculosis Lancet 2003 362 887 899
5. Reichman L.B. Hershfield E.S. Tuberculosis: A Comprehensive International Approach Marcel Dekker Inc. New York, NY, USA 2000 401 433
6. Katherine M.C. Anton L.P. Mohammed L. Marta B. Pharmacology of second-line antituberculosis drugs and potential for interactions with antiretroviral agents AIDS 2009 23 437 446 10.1097/QAD.0b013e328326ca50
7. Marra F. Marra C.A. Moadebi S. Shi P. Elwood R.K. Stark G. FitzGerald J.M. Levofloxacin treatment of active tuberculosis and the risk of adverse events Chest 2005 128 1406 1413 10.1378/chest.128.3.1406
8. Rodriguez J.C. Ruiz M. Climent A. Royo G. In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis Int. J. Antimicrob. Agents 2001 17 229 231 10.1016/S0924-8579(00)00337-X
9. Rodriguez J.C. Ruiz M. Lopez M. Royo G. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis Int. J. Antimicrob. Agents 2002 20 464 467 10.1016/S0924-8579(02)00239-X
10. Traini D. Young P.M. Delivery of antibiotics to the respiratory tract: An update Expert Opin. Drug Deliv. 2009 6 897 905 10.1517/17425240903110710
11. King P. Lomovskaya O. Griffith D.C. Burns J.L. Dudley M.N. In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis Antimicrob. Agents Chemother. 2010 54 143 148
12. Geller D.E. Flume P.A. Griffith D.C. Morgan E. White D. Loutit J.S. Dudley M.N. Pharmacokinetics and safety of MP-376 (Levofloxacin inhalation solution) in cystic fibrosis subjects Antimicrob. Agents Chemother. 2011 55 2636 2640 10.1128/AAC.01744-10
13. Telko M.J. Hickey A.J. Dry powder inhaler formulation Respir. Care 2005 50 1209 1227
14. Rojanarat W. Changsan N. Tawithong E. Pinsuwan S. Chan H.K. Srichana T. Isoniazid proliposome powders for inhalation-preparation, characterization and cell cuture studies Int. J. Mol. Sci. 2011 12 4414 4434 10.3390/ijms12074414
15. Sawatdee S. Worakul N. Srichana T. Preparation of isoniazid as dry powder formulations for inhalation by physical mixing and spray drying Malaysian J. Pharm. Sci. 2006 4 43 63
16. Daniher D.I. Zhu J. Dry powder platform for pulmonary drug delivery Particuology 2008 6 225 238 10.1016/j.partic.2008.04.004
17. Calvert G. Ghadiri M. Tweedie R. Aerodynamic dispersion of cohesive powders: A review of understanding and technology Adv. Powder Technol. 2009 20 4 16 10.1016/j.apt.2008.09.001
18. United State Pharmacopeial Convention Guideline No. 905: Uniformity of dosage units US Pharmacopeia 30-NF 25 US Pharmacopeial Convention US Pharmacopeial Convention, Inc. Rockville, USA 2007 378 384
19. Song K.H. Chung S.J. Shim C.K. Preparation and evaluation of proliposomes containing salmon calcitonin J. Contr. Release 2002 84 27 37
20. Wagner A. Vorauer-Uhl K. Liposome technology for industrial purposes J. Drug Deliv. 2011 2011
21. Kanchan V. Panda A.K. Interactions of antigen-loaded polylactide particles with macrophages and their correlation with the immune response Biomaterials 2007 28 5344 5357 10.1016/j.biomaterials.2007.08.015
22. Thompson A.K. Couchoud A. Singh H. Comparison of hydrophobic and hydrophilic encapsulation using liposomes prepared from milk fat globule-derived phospholipids and soya phospholipids Dairy Sci. Tech. 2009 89 99 113 10.1051/dst/2008036
23. Chen H. Gao J. Wang F. Liang W. Preparation, characterization and pharmacokinetics of liposomes-encapsulated cyclodextrins inclusion complexes for hydrophobic drugs Drug Deliv. 2007 14 201 208
24. Chang C.C. Liu D.Z. Lin S.Y. Liang H.J. Hou W.C. Huang W.J. Chang C.H. Ho F.M. Liang Y.C. Liposome encapsulation reduces cantharidin toxicity Food Chem. Toxicol. 2008 46 3116 3121 10.1016/j.fct.2008.06.084
25. Tsivkovskii R. Sabet M. Tarazi Z. Griffith D.C. Lomovskaya O. Dudley M.N. Levofloxacin reduces inflammatory cytokine levels in human bronchial epithelia cells: Implications for aerosol MP-376 (levofloxacin solution for inhalation) treatment of chronic pulmonary infections FEMS Immunol. Med. Microbiol. 2011 61 141 146 10.1111/j.1574-695X.2010.00755.x
26. Rastogi N. Goh K.S. Bryskier A. Devallois A. In vitro activities of levofloxacin used alone and in combination with first- and second-line antituberculosis drugs against Mycobacterium tuberculosis Antimicrob. Agents Chemother. 1996 40 1610 1616
27. Sharp P.E. LaRegina M.C. The laboratory rat The Laboratory Animal Pocket Reference Series Suckow M.A. CRC Press LLC Florida, FL, USA 1998 17
28. Johnston D.E. Special considerations in interpreting liver function tests Am. Fam. Physician. 1999 59 2223 2230
29. Srichana T. Suedee R. Srisudjai P. Application of spectrofluorometry for evaluation of dry powder inhalers in vitro Pharmazie 2003 58 125 129
30. Atkins P.J. Crowder T.E. The design and development of inhalation drug delivery systems Pharmaceutical Inhalation Aerosol Technology Hickey A.J. Marcel Dekker New York, NY, USA 2004
31. Saetern A.M. Flaten G.E. Brandl M. A method to determine the incorporation capacity of camptothecin in liposomes AAPS PharmSciTech 2004 5 30 37
32. Morris K.R. Rodriguez-Hornedo N. Hydrates Encyclopedia of Pharmaceutical Technology Swarbrick J. Boylan J.C. Marcel Dekker New York, NY, USA 1993 393 440
33. Huttunen K. Ruotsalainen M. Iivanainen E. Torkko P. Katila M.L. Hirvonen M.R. Inflammatory responses in RAW 264.7 macrophages caused by mycobacteria isolated from moldy houses Environ. Toxicol. Pharmacol. 2000 8 237 244 10.1016/S1382-6689(00)00047-8
34. Punturee K. Wild C.P. Vinitketkumneun U. Thai medicinal plants modulate nitric oxide and tumor necrosis factor in J774.2 mouse macrophage J. Ethnopharmacol. 2004 95 183 189 10.1016/j.jep.2004.06.019
35. Ritelli M. Amadori M. Tagliabue S. Pacciarini M.L. Use of a macrophage cell line for rapid detection of Mycobacterium bovis in diagnostic samples Vet. Microbiol. 2003 94 105 120 10.1016/S0378-1135(03)00080-4
36. Collins L.A. Franzblau S.G. Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium Antimicrob. Agents Chemother. 1997 41 1004 1009
37. Brain J.D. Knudson D.E. Sorokin S.P. Davis M.A. Pulmonary distribution of particles given by intratracheal instillation or by aerosol inhalation Environ. Res. 1976 11 13 33 10.1016/0013-9351(76)90107-9